FDA Approved: XTANDI — Original Application (Astellas Pharma US, Inc.)

View source ↗

Summary

FDA approves XTANDI (enzalutamide) under the original application NDA213674 for metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xtandi (enzalutamide)

Snippet

ORIG AP for XTANDI (ENZALUTAMIDE)